Introducing Adam Takos, Vice President of Drug Innovation and Managing Director of Singapore

In today’s blog, we are pleased to introduce Adam Takos, Vice President of Drug Innovation and Managing Director of Singapore.
Introducing Andrew Saarni, Director, Fermentation Process Development & Scale-Up

In today’s blog, we are pleased to introduce Andrew Saarni, Head of Fermentation Process Development & Scale-Up at Antheia.
Future of Pharma Insights: Q&A with Antheia and TAPI
As global pharma leaders convene in New York City for DCAT Week 2026, Antheia is proud to highlight its strategic partnership with TAPI – Technology and API Services.
Introducing Chris Savile, Vice President, Business Development and Partnerships

We sat down with Chris to learn more about his career journey, what inspired him to join Antheia’s mission, and what he’ll focus on in this new role.
Antheia’s 2025 in Review: A Year Of Momentum

As 2025 draws to a close, we’re reflecting on a year defined by momentum. With commercial products to market and a growing ecosystem of partners, we are continuing to realize our vision for a new era of pharmaceutical manufacturing and innovation. Through advanced biosynthesis, we’re transforming how the pharmaceutical industry develops and manufactures the medicines the world needs. […]
Introducing Eric d’Esparbes, Chief Financial Officer

Today, Antheia is pleased to announce the appointment of pharma and biotech finance veteran Eric d’Esparbes as Chief Financial Officer. Ahead of today’s announcement, we sat down with Eric to learn more about his career journey, what inspired him to join Antheia’s mission, and what he’ll focus on in this new role: Tell us about […]
Future of Pharma Insights: Q&A with Antheia and Phlow

We sat down with Dr. Kristy Hawkins, Co-Founder and Chief Scientific Officer at Antheia and Dr. Andrew Carpenter, Chief Scientific Officer at Phlow Corp. to discuss the new partnership, the current state of pharmaceutical manufacturing, and what the future holds for American medicine production.
Celebrating Antheia’s Series C Financing
After a busy year marked by major commercial milestones for Antheia, we are excited to announce $56 million in Series C financing. With the support of new and existing investors, we are entering a new chapter as a business, bringing us closer than ever to a world without essential medicine shortages.
Antheia’s Head of Commercialization, Richard Sherwin on DCAT Week 2025

This week the Drug, Chemical & Associated Technologies Association (DCAT) will host DCAT Week 2025 in New York City, an annual event bringing together companies from across the bio/pharmaceutical manufacturing value chain. We sat down with Richard Sherwin, Antheia’s SVP of Commercialization, to learn more about the importance of the event for the future of […]
Introducing Farrah Pulce, Head of Project Management

In today’s blog, we are pleased to introduce Farrah Pulce, Head of Project Management at Antheia. Farrah helps every team across the company stay on track toward our collective goals, and her work played a crucial role in our first commercial delivery of thebaine. We sat down with Farrah to learn more about her background […]